Oruka Therapeutics, Inc. Common Stock (ORKA)

• Market cap: $841M
• 1 day: 0.17%
• 5 days: -9.90%
• 1 month: -13.59%
• 3 months: -14.11%
• 6 months: -14.11%
• Year to date: -14.11%
• 1 year: -14.11%
• 5 years: -14.11%
• 10 years: -14.11%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

About: Oruka Therapeutics Inc is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. It is to offer patients suffering from chronic skin diseases like plaque psoriasis.

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1,064% more capital invested

Capital invested by funds: $51.9M [Q2] → $604M (+$552M) [Q3]

300% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 4 (+3) [Q3]

208% more call options, than puts

Call options by funds: $453K | Put options by funds: $147K

77% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 13

70.17% more ownership

Funds ownership: 0% [Q2] → 70.17% (+70.17%) [Q3]

32% more funds holding

Funds holding: 31 [Q2] → 41 (+10) [Q3]

50% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 12

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $40 66% upside
• Avg. target: $44 81% upside
• High target: $49 104% upside

8 analyst ratings

• positive: 8 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Mitchell Kapoor 42% 1-year accuracy 61 / 146 met price target	87% upside $45	Buy Reiterated	31 Oct 2024
Stifel Alex Thompson 60% 1-year accuracy 6 / 10 met price target	104% upside $49	Buy Initiated	11 Oct 2024
HC Wainwright & Co. Mitchell Kapoor 42% 1-year accuracy 61 / 146 met price target	87% upside $45	Buy Initiated	7 Oct 2024
Leerink Partners David Risinger 38% 1-year accuracy 3 / 8 met price target	83% upside $44	Outperform Initiated	17 Sept 2024
Leerink Swann David Risinger 38% 1-year accuracy 3 / 8 met price target	83% upside $44	Outperform Initiated	17 Sept 2024